Publications by authors named "M Sanchez-Solis"
Article Synopsis
- The study investigates how body mass index (BMI) and weight gain in healthy infants can impact lung function, specifically focusing on the balance between forced expiratory volume (FEV) and forced vital capacity (FVC).
- Researchers measured lung function in 69 healthy infants and defined dysanapsis (an imbalance between FEV and FVC) using specific criteria.
- The results indicated that higher BMI is linked to an increased risk of dysanapsis, suggesting that lung function development may be affected by weight gain in infants, even if they are not considered obese.*
In 2016, the Spanish Research Group on Bronchopulmonary Dysplasia (BPD) (GEIDIS) established a national registry with participation of 66 hospitals to collect information on clinical characteristics and long-term outcomes of BPD infants into adulthood. The aim of this observational study is to examine forced spirometry data in early childhood and to assess their correlation with the respiratory support required at 36 weeks postmenstrual age (PMA). The study analyzed data from preterm infants with BPD born between January 2016 and December 2017 who underwent forced spirometry at 5-7 years of age.
View Article and Find Full Text PDFAsthma is a heterogeneous and very complex group of diseases, and includes different clinical phenotypes depending on symptoms, progression, exacerbation patterns, or responses to treatment, among other characteristics. The allergic phenotype is the most frequent, especially in pediatric asthma. It is characterized by sensitization (the production of specific IgEs) to allergens and frequent comorbidity with rhinitis as well as atopic dermatitis.
View Article and Find Full Text PDFArticle Synopsis
- Recognizing the different phenotypes of pediatric asthma allows for tailored treatment options, focusing on specific underlying mechanisms and biomarkers.
- Biologic therapies are increasingly significant for treating severe asthma in children, particularly targeting the most common T2 phenotype.
- This review discusses the action, effectiveness, and potential biomarkers of several biologic drugs—omalizumab, mepolizumab, benralizumab, dupilumab, and 1ezepelumab—highlighting varying prescription guidelines between the FDA and EMA.
Article Synopsis
- * The review discusses protective and risk factors associated with asthma, examines current treatment options, and explores the body's immune response, including changes to the epithelial barrier.
- * Additionally, it addresses the genetic and epigenetic influences on asthma and virus susceptibility, as well as the relationship between childhood respiratory infections and the onset of asthma.*